Drug firm Alembic Pharmaceuticals today said it has received establishment inspection report (EIR) from the US health regulator for its Karakhadi facility in Gujarat.
The company has received EIR from the United States Food and Drug Administration (USFDA) for the inspection carried out at the active pharmaceutical ingredient facility at Karakhadi from May 14-18, 2018, Alembic Pharmaceuticals said in a BSE filing.
"With this, all our manufacturing facilities for international markets are FDA compliant," it added.
An establishment inspection report is given by the US health regulator USFDA on closure of inspection of an establishment.
Shares of Alembic Pharmaceuticals today closed 0.50 per cent lower at Rs 513.75 per scrip on the BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
